Skip to Main Content

Author Details

Judy C Boughey
Mayo Clinic
2001
422
57
PMIDPaper TitleJournal TitlePublished Year
37872454Lobular-Like Features and Outcomes of Mixed Invasive Ductolobular Breast Cancer (MIDLC): Insights from 54,403 Stage I-III MIDLC Patients.Ann Surg Oncol2024
37878154Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer.Breast Cancer Res Treat2024
36305029Response Rates of Invasive Lobular Cancer in Patients Undergoing Neoadjuvant Endocrine or Chemotherapy.Am Surg2023
37714645Lasting Impacts of the COVID-19 Pandemic on Breast Cancer Diagnosis and Treatment in the United States.Surg Oncol Clin N Am2023
37488395ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management.Ann Surg Oncol2023
37707811Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial.JAMA Netw Open2023
37589839Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.Breast Cancer Res Treat2023
37516725ASO Visual Abstract: Clinical Behavior, Management, and Treatment Response of Estrogen Receptor-Low (1-10%) Breast Cancer.Ann Surg Oncol2023
37615191Lessons learned from the COVID-19 pandemic: Using telemedicine for pre-operative surgical evaluation in breast disease.J Telemed Telecare2023
37696281Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.Lancet Oncol2023
37460743Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer.Ann Surg Oncol2023
37325931Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.Ann Surg2023
36993608Clinical Outcomes and Prognostic Factors in Triple-Negative Invasive Lobular Carcinoma of the Breast.Res Sq2023
37251618Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data.Clin Transl Radiat Oncol2023
37380911Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.Ann Surg Oncol2023
37210429Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast.Breast Cancer Res Treat2023
37244627Postmastectomy Intensity Modulated Proton Therapy: 5-Year Oncologic and Patient-Reported Outcomes.Int J Radiat Oncol Biol Phys2023
36977292Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance).J Clin Oncol2023
37277309First steps into synoptic operative reporting in breast cancer surgery: A journey to improve quality cancer care.Surgery2023
37072398Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer.Nat Commun2023
36971986Reply to: "The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial: A Comment" by Alser, Osaid.Ann Surg Oncol2023
37226243Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumors.Breast Cancer Res2023
36653664Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.Ann Surg Oncol2023
36808041Outcomes of robotic nipple-sparing mastectomy versus conventional nipple-sparing mastectomy in women with breast cancer: a systematic review and meta-analysis.J Robot Surg2023
36745260ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer.Ann Surg Oncol2023
36689092Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.Breast Cancer Res Treat2023
36469363Pharmacological Targeting of Androgen Receptor Elicits Context-Specific Effects in Estrogen Receptor-Positive Breast Cancer.Cancer Res2023
33160859MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.Acad Radiol2022
35734391Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.NAR Cancer2022
35609361National Cancer Database trends in surgical resection of the breast primary for stage IV breast cancer.Surg Oncol2022
35834142Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer.Ann Surg Oncol2022
35578060The EA2108 Clinical Trial and Real-World Data: A Cautionary Tale in Stage IV Breast Cancer.Ann Surg Oncol2022
35832147Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation.Arch Plast Surg2022
35794363ASO Author Reflections: In an Era of De-escalation, Are We Still Doing Too Much for Stage 0 Breast Cancer?Ann Surg Oncol2022
35789303Overuse of Axillary Surgery in Patients with Ductal Carcinoma In Situ: Opportunity for De-escalation.Ann Surg Oncol2022
35854027Node Positivity Among Sonographically Suspicious but FNA-Negative Axillary Nodes.Ann Surg Oncol2022
35569077Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67.Ann Surg Oncol2022
35486168Ultrasound high-definition microvasculature imaging with novel quantitative biomarkers improves breast cancer detection accuracy.Eur Radiol2022
35451727Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.Ann Surg Oncol2022
35713802Surveillance mammography after treatment for male breast cancer.Breast Cancer Res Treat2022
35385996Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?Ann Surg Oncol2022
35776260ASO Visual Abstract: Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer-Effects of Age and Tumor Ki67.Ann Surg Oncol2022
35849283Lack of Clinical Value for Immunohistochemistry for Sentinel Lymph Node Assessment in Invasive Lobular Carcinoma.Ann Surg Oncol2022
36554065Current Considerations in Surgical Treatment for Adolescents and Young Women with Breast Cancer.Healthcare (Basel)2022
36458203Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer.Mol Ther Oncolytics2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
36109410ASO Visual Abstract: Node Positivity Among Sonographically Suspicious but FNA-Negative Axillary Nodes.Ann Surg Oncol2022
35871670ASO Visual Abstract: Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk.Ann Surg Oncol2022
35870053ASO Visual Abstract: Lack of Clinical Value for Immunohistochemistry for Sentinel Lymph Node Assessment in Invasive Lobular Carcinoma.Ann Surg Oncol2022
36069821Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.JAMA Surg2022
  • 1 - 50 of 422

Recommended Authors

Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 13
50148Janssen Pharmaceutica NV
Career Start Year 2014
Number of shared co-authors 7
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 8
University of Maryland School of Medicine
Career Start Year 2010
Number of shared co-authors 1
University of Milano
Career Start Year 2008
Number of shared co-authors 1
Maricopa Medical Center
Career Start Year 2007
Number of shared co-authors 1
University of Virginia School of Medicine
Career Start Year 2007
Number of shared co-authors 0
The Ottawa Hospital Cancer Centre
Career Start Year 2006
Number of shared co-authors 0
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 8
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 10
Massachusetts General Hospital Cancer Center
Career Start Year 2004
Number of shared co-authors 10
Samsung Medical Center, Sungkyunkwan University School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Erasmus MC Cancer Institute
Career Start Year 2004
Number of shared co-authors 11
Massachusetts General Hospital
Career Start Year 2003
Number of shared co-authors 3
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 3
Otto-Friedrich-University Bamberg
Career Start Year 2002
Number of shared co-authors 24
Champalimaud Clinical Center/Champalimaud Foundation
Career Start Year 2000
Number of shared co-authors 16
Universite Libre de Bruxelles
Career Start Year 2000
Number of shared co-authors 4
Ironwood Cancer and Research Centers, AZ Arizona Cancer Center, University of Arizona
Career Start Year 1999
Number of shared co-authors 3
Clinica Universidad de Navarra, Cancer Center Universidad de Navarra
Career Start Year 1998
Number of shared co-authors 11
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 10
Radboud University Medical Center
Career Start Year 1994
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1993
Number of shared co-authors 11
Institute of Cancer and Genomic Sciences, The University of Birmingham
Career Start Year 1993
Number of shared co-authors 3
University Health Network
Career Start Year 1992
Number of shared co-authors 1
Dartmouth-Hitchcock Medical Center
Career Start Year 1990
Number of shared co-authors 1
National and Kapodistrian University of Athens
Career Start Year 1987
Number of shared co-authors 3
Queen Elizabeth University Hospital
Career Start Year 1986
Number of shared co-authors 2
Walter Reed National Military Medical Center
Career Start Year 1985
Number of shared co-authors 4
Dana-Farber Cancer Institute
Career Start Year 1985
Number of shared co-authors 26

Collaborators

Division of Biostatistics and Clinical Trials, Mayo Clinic
Co-authored papers 96
Mayo Clinic
Co-authored papers 86
Mayo Clinic
Co-authored papers 64
The University of Texas MD Anderson Cancer Center
Co-authored papers 50
Department of Health Services Research, Mayo Clinic
Co-authored papers 37
Mayo Clinic
Co-authored papers 32
Co-authored papers 22
Mayo Clinic
Co-authored papers 22
Mayo Clinic
Co-authored papers 19
Co-authored papers 19
Mayo Clinic
Co-authored papers 19
Mayo Clinic
Co-authored papers 17
University of Texas MD Anderson Cancer Center
Co-authored papers 16
Mayo Clinic
Co-authored papers 15
University of California San Francisco
Co-authored papers 14
University of California San Francisco
Co-authored papers 14
Co-authored papers 13
Co-authored papers 13
MD Anderson Cancer Center
Co-authored papers 12
Mayo Clinic
Co-authored papers 11
Mayo Clinic
Co-authored papers 11
Co-authored papers 10
Mayo Clinic
Co-authored papers 8
Department of Medicine and Moores Cancer Center, University of California San Diego
Co-authored papers 8
Moores Cancer Center, University of California San Diego
Co-authored papers 8
University of Kansas Medical Center
Co-authored papers 7
Inova Health System
Co-authored papers 7
Center for Cancer Research, National Cancer Institute
Co-authored papers 7
Co-authored papers 7
Co-authored papers 6